Codeine
From open-encyclopedia.com - the free encyclopedia.
- For the rock band of this name see Codeine (band).
|
| |
| (5R,6S)-7,8-didehydro-4,5-epoxy- 3-methoxy-N-methylmorphinan-6-ol | |
| CAS number 76-57-3 (anhydrous) | ATC code ? |
| Chemical formula | C18H21NO3 |
| Molecular weight | 299.4 |
| Bioavailability | ? |
| Metabolism | hepatic |
| Elimination half-life | 3-4 hours |
| Excretion | renal |
| Pregnancy category | Category A (Australia) |
| Legal status | Schedule 8 (Australia), Schedule II (United States) |
| Routes of administration | oral, SC, IM |
Codeine (INN) is an opioid used for its analgesic, antitussive and antidiarrhoeal properties. It is commonly marketed as the phosphate salt codeine phosphate.
Codeine is an alkaloid found in opium in concentrations ranging from 0.7 to 2.5 percent. While codeine can be extracted from opium, most codeine used in the United States is synthesized from morphine through the process of methylation.
| Contents |
Indications
Approved indications for codeine include:
- cough - though its efficacy has been disputed (Schroeder & Fahey, 2001)
- diarrhoea
- mild-to-moderate pain
Codeine is sometimes marketed in combination preparations with paracetamol (co-codamol), aspirin (co-codaprin) or ibuprofen; for mild-to-moderate pain. These combinations provide greater pain relief than either agent used singly.
Pharmacokinetics
Codeine is considered a prodrug, since it is metabolised in vivo to the principal active analgesic agent morphine. It is, however, less potent than morphine since only about 10% of the codeine is converted. It also has a correspondingly lower dependence-liability than morphine.
Theoretically, a dose of approximately 200mg (oral) of codeine must be administered to give equivalent analgesia to 30mg (oral) of morphine (Rossi, 2004). It is not used, however, in single doses of greater than 60mg (and no more than 240mg in 24 hours) since there is a ceiling effect.
The conversion of codeine to morphine occurs in the liver and is catalysed by the cytochrome P450 enzyme CYP2D6. Approximately 6-10% of the Caucasian population have poorly functional CYP2D6 and codeine is virtually ineffective for analgesia in these patients (Rossi, 2004). Many of the adverse effects, however, are still experienced.
Pharmacology
Main article: opioid receptor
Codeine itself has weak affinity for the μ-opioid receptor. Its principal analgesic actions are mediated by the affinity of morphine for the μ-opioid receptor, though other therapeutic and adverse effects are produced by activation of other opioid receptors.
Adverse effects
Common adverse drug reactions (ADRs) associated with the use of codeine include: nausea, vomiting, drowsiness, dry mouth, miosis, orthostatic hypotension, urinary retention and constipation. (Rossi, 2004)
With prolonged use, tolerance develops to many of the effects of opioids such as codeine, including the adverse effects.
A potentially serious ADR, as with other opioids, is respiratory depression. This depression is dose-related and is the mechanism for the potentially fatal consequences of overdose.
Abuse/misuse
Codeine is often abused as a "recreational drug". This may be due to its easy availability over-the-counter or on prescription in combination products (which are scheduled lower than codeine as a single-agent). Users abuse it in order to obtain the euphoric effects associated with use of opioids such as codeine. Commonly these users will purchase large quantities of co-codamol tablets, and consume these at higher-than-recommended doses, without apparent concern of the hepatotoxicity associated with large doses of paracetamol.
Certain codeine products are encountered on the illicit market, frequently in combination with glutethimide (Doriden) or carisoprodol (Soma).
References
- Rossi S (Ed.) (2004). Australian Medicines Handbook 2004. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-4-2.
- Schroeder K & Fahey T (2004). Over-the-counter medications for acute cough in children and adults in ambulatory settings. The Cochrane Database of Systematic Reviews 2004 (4), DOI:10.1002/14651858.CD001831.pub2.
See also
| ] | |||||
|---|---|---|---|---|---|
|
| ||||
de:Codein
eo:Kodeino
fr:Codéine
ms:Kodeina
nl:Codeïne
pl:Kodeina
sv:Kodein